Cardiovascular Effects of Immune Checkpoint Inhibitors : More Than Just Myocarditis
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: Immune checkpoint inhibitors have reshaped the treatment of cancer, but they are characterized by peculiar toxicity consisting of immune-related adverse events that may potentially affect any organ or system. In this review, we summarize data on clinical presentation, diagnosis, pathogenesis, and management of the main immune-related cardiovascular toxicities of immune checkpoint inhibitors.
RECENT FINDINGS: The most relevant immune-related cardiovascular toxicity is myocarditis, but other non-negligible reported events include non-inflammatory heart failure, conduction abnormalities, pericardial disease, and vasculitis. More recently, growing evidence suggests a role for immune checkpoint inhibitors in accelerating atherosclerosis and promoting plaque inflammation, thus leading to myocardial infarction. Immune checkpoint inhibitors are associated with several forms of cardiovascular toxicity; thus, an accurate cardiovascular baseline evaluation and periodical monitoring are required. Furthermore, the optimization of cardiovascular risk factors before, during, and after treatment may contribute to mitigating both short-term and long-term cardiovascular toxicity of these drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current oncology reports - 25(2023), 7 vom: 05. Juli, Seite 743-751 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inno, Alessandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 24.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11912-023-01411-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355225433 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355225433 | ||
| 003 | DE-627 | ||
| 005 | 20231226063912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-023-01411-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355225433 | ||
| 035 | |a (NLM)37017825 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inno, Alessandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular Effects of Immune Checkpoint Inhibitors |b More Than Just Myocarditis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: Immune checkpoint inhibitors have reshaped the treatment of cancer, but they are characterized by peculiar toxicity consisting of immune-related adverse events that may potentially affect any organ or system. In this review, we summarize data on clinical presentation, diagnosis, pathogenesis, and management of the main immune-related cardiovascular toxicities of immune checkpoint inhibitors | ||
| 520 | |a RECENT FINDINGS: The most relevant immune-related cardiovascular toxicity is myocarditis, but other non-negligible reported events include non-inflammatory heart failure, conduction abnormalities, pericardial disease, and vasculitis. More recently, growing evidence suggests a role for immune checkpoint inhibitors in accelerating atherosclerosis and promoting plaque inflammation, thus leading to myocardial infarction. Immune checkpoint inhibitors are associated with several forms of cardiovascular toxicity; thus, an accurate cardiovascular baseline evaluation and periodical monitoring are required. Furthermore, the optimization of cardiovascular risk factors before, during, and after treatment may contribute to mitigating both short-term and long-term cardiovascular toxicity of these drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Conduction disease | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Myocardial infarction | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Pericardial disease | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Tarantini, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Parrini, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Spallarossa, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Maurea, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bisceglia, Irma |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestris, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Gori, Stefania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d 1999 |g 25(2023), 7 vom: 05. Juli, Seite 743-751 |w (DE-627)NLM110371534 |x 1534-6269 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:7 |g day:05 |g month:07 |g pages:743-751 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11912-023-01411-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 7 |b 05 |c 07 |h 743-751 | ||